Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis

Histology and Histopathology

Volumn 19, Issue 1, 2004, Pages 239-250

  Thiele, Juergen ^a   Kvasnicka, H M ^a   Schmitt Graff A ^b   Hulsemann R ^a   Diehl, V ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

BM biopsies; BM changes; Chemotherapy; Fibrosis; Idiopathic myelofibrosis; Interferon; Myelodysplasia

Indexed keywords

ALPHA2B INTERFERON; BUSULFAN; CYTARABINE; HYDROXYUREA; INTERFERON; RETICULIN;

APLASIA; BIOPSY; BONE MARROW; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CLINICAL FEATURE; COMPARATIVE STUDY; DATA ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG INHIBITION; DRUG TOLERABILITY; EDEMA; ERYTHROID PRECURSOR CELL; EVIDENCE BASED MEDICINE; FIBROSIS; FOLLOW UP; HEMATOPOIESIS; HUMAN; HYPOPLASIA; MEDICAL LITERATURE; MEGAKARYOCYTE; MYELODYSPLASIA; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PALLIATIVE THERAPY; QUANTITATIVE ANALYSIS; REVIEW; SCLEREDEMA; SPINAL CORD DISEASE; STEM CELL TRANSPLANTATION; SYMPTOMATOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOPSY; BONE MARROW; BUSULFAN; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; INTERFERONS; MYELOFIBROSIS;

EID: 1642514983     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Anderson J.E., Sale G., Appelbaum F.R., Chauncey T.R. and Storb R. (1997). Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br. J. Haematol. 98, 1010-1016.
2. Anger B., Seidler R., Haug U., Pop C. and Heimpel H. (1990). Idiopathic myelofibrosis: A retrospective study of 103 patients. Haematologica 75, 228-234.
3. Bachleitner-Hofmann T. and Gisslinger H. (1999). The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Ann. Hematol. 78, 533-538.
4. Bain B.J. (1999). The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Leuk. Lymphoma. 34, 443-449.
5. Barosi G. (1999). Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J. Clin. Oncol. 17, 2954-2970.
6. Barosi G., Berzuini C., Liberato L.N., Costa A., Polino G. and Ascari E. (1988). A prognostic classification of myelofibrosis with myeloid metaplasia. Br. J. Haematol. 70, 397-401.
7. Barosi G., Liberato L.N., Costa A., Buratti A., Di Dio F., Salvatore S. and Ascari E. (1990). Induction and maintenance alpha-interferon therapy in myelofibrosis with myelofibrosis with myeloid metaplasia. Eur. J. Haematol. Suppl. 52, 12-14.
8. Bartl R., Frisch B. and Wilmanns W. (1993). Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD). Eur. J. Haematol. 50, 41-52.
9. Bauermeister D.E. (1971). Quantitation of bone marrow reticulin - A normal range. Am. J. Clin. Pathol. 56, 24-31.
10. Bilgrami S. and Greenberg B.R. (1995). Polycythemia rubra vera. Semin. Oncol. 22, 307-326.
11. Buesche G., Georgii A., Duensing A., Schmeil A., Schlue J. and Kreipe H.H. (2003). Evaluating the volume ratio of bone marrow affected by fibrosis: A parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Hum. Pathol. 34, 391-401.
12. Buhr T., Georgii A. and Choritz H. (1993). Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol. Res. Pract. 189, 121-132.
13. Buhr T., Buesche G., Choritz H., Langer F. and Kreipe H. (2003). Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidence in sequential bone marrow biopsy specimens. Am. J. Clin. Pathol 119, 152-158.
14. Cervantes F., Pereira A., Esteve J., Cobo F., Rozman C. and Montserrat E. (1998). The changing profile of idiopathic myelofibrosis: A comparison of the presenting features of patients diagnosed in two different decades. Eur. J. Haematol. 60, 101-105.
15. Cervantes F., Alvarez-Larran A., Talarn C., Gomez M. and Montserrat E. (2002). Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: Actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br. J. Haematol. 118, 786-790.
16. Ellis J.T., Peterson P., Geller S.A. and Rappaport H. (1986). Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin. Hematol. 23, 144-155.
17. Finazzi G. and Barbui T. (1999). Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann. Hematol. 78, 389-392.
18. Finazzi G., Ruggeri M., Rodeghiero F. and Barbui T. (2000). Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial. Br. J. Haematol. 110, 577-583.
19. Frisch B., Bartl R. and Chaichik S. (1986). Therapy-induced myelodysplasia and secondary leukaemia. Scand. J. Haematol. Suppl. 45, 38-47.
20. Furgerson J.L., Vukelja S.J., Baker W.J. and O'Rourke T.J. (1996). Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am. J. Hematol. 51, 137-140.
21. Georgii A., Vykoupil K.F., Buhr T., Choritz H., Doehler U., Kaloutsi V. and Werner M. (1990). Chronic myeloproliferative disorders in bone marrow biopsies. Pathol. Res. Pract. 186, 3-27.
22. Georgii A., Buesche G. and Kreft A. (1998). The histopathology of chronic myeloproliferative diseases. Baillieres Clin. Haematol. 11, 721-749.
23. Gilbert H.S. (1998). Long term treatment of myeloproliferative disease with interferon-alpha-2b: Feasibility and efficacy. Cancer 83, 1205-1213.
24. Guardiola P., Anderson J.E., Bandini G., Cervantes F., Runde V., Arcese W., Bacigalupo A., Przepiorka D., O'Donnell M.R., Polchi P., Buzyn A., Sutton L., Cazals-Hatem D., Sale G., de Witte T., Deeg H.J. and Gluckman E. (1999). Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93, 2831-2838.
25. Gupta R., Abdalla S.H. and Bain B.J. (1999). Thrombocytosis with sideroblastic erythropoiesis: A mixed myeloproliferative myelodysplastic syndrome. Leuk. Lymphoma 34, 615-619.
26. Hasselbalch H.C. (1993). Idiopathic myelofibrosis - An update with particular reference to clinical aspects and prognosis. Int. J. Clin. Lab. Res. 23, 124-138.
27. Hasselbalch H. and Lisse I. (1991). A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis. Eur. J. Haematol. 46, 285-289.
28. Higuchi T., Okada S., Mori H., Niikura H., Omine M. and Terada H. (1995). Leukemic transformation of polycythemia vera and essential thrombocytocythemia possibly associated with an alkylating agent. Cancer 75, 471-477.
29. Hurwitz N. (1997). Bone marrow trephine biopsy changes following chemotherapy and/or bone marrow transplantation. Curr. Diagn. Pathol. 4, 196-202.
30. Krech R. and Thiele J. (1985). Histopathology of the bone marrow in toxic myelopathy. A study of drug induced lesions in 57 patients. Virchows Arch A. 405, 225-235.
31. Kreft A., Reimann J. and Choritz H. (2000). Fibre content and cellularity of the bone marrow of the iliac crest, vertebral column and sternum in chronic myeloproliferative disorders. Leuk. Lymphoma 38, 165-173.
32. Le Bousse-Kerdiles M.C. and Martyre M.C. (1999a). Myelofibrosis: Pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia. Springer Semin. Immunopathol. 21, 491-508.
33. Le Bousse-Kerdiles M.C. and Martyre M.C. (1999b). Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann. Hematol. 78, 437-444.
34. Liozon E., Brigaudeau C., Trimoreau F., Desangles F., Fermeaux V., Praloran V. and Bordessoule D. (1997). Is treatment with hydroxyurea leukemogenic in patients with essential thrombocytopenia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol. Cell. Ther. 39, 11-18.
35. Loefvenberg E., Wahlin A., Roos G. and Ost A. (1990). Reversal of myelofibrosis by hydroxyurea. Eur. J. Haematol. 44, 33-38.
36. Lohmann T.P. and Beckman E.N. (1983). Progressive myelofibrosis in agnogenic myeloid metaplasia. Arch. Pathol. Lab. Med. 107, 593-594.
37. Mavrogianni D., Vianiou N., Michali E., Terpos E., Meletis J., Vaiopoulos G., Madzourani M., Pangalis G., Yataganas X. and Loukopoulos D. (2002). Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatelite instability in chromosomes 5 and 7 in 69 patients. Int. J. Hematol. 75, 394-400.
38. Michelson J.D., Gornet M., Codd T., Torres J., Lanighan K. and Jones R. (1993). Bone morphology after bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Exp. Hematol. 21, 475-482.
39. Nand S., Stock W., Godwin J. and Fisher S.G. (1996). Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am. J. Hematol. 52, 42-46.
40. Nielsen II. and Hasselbalch H.C. (2003). Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxylurea alone or with hydroxyurea after busulphan. Am. J. Hematol. 74, 26-31.
41. Parmeggani L., Ferrant A., Rodhain J., Michaux J.L. and Sokal G. (1987). Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur. J. Haematol. 39, 228-232.
42. Randi M.L., Fabris F. and Girolami A. (2000). Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk. Lymphoma 37, 379-385.
43. Rigolin G.M., Cuneo A., Roberti M.G., Bardi A., Bigoni R., Piva N., Minotto C., Agostini P., De Angeli C., Del Senno L., Spanedda R. and Castoldi G. (1998). Exposure to myelotoxic agents and myelodysplasia: Case-control study and correlation with clinicobiological findings. Br. J. Haematol. 103, 189-197.
44. Rousselet M.C., Kerjean A., Guyetant S., Francois S., Saint-Andre J.P. and Ifrah N. (1996). Histopathology of bone marrow after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Pathol. Res. Pract. 192, 790-795.
45. Sacchi S. (1995). The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): A concise update. Leuk. Lymphoma. 19, 13-20.
46. Smith R.E., Chelmowski M.K. and Szabo E.J. (1988). Myelofibrosis: A concise review of clinical and pathologic features and treatment. Am. J. Hematol. 29, 174-180.
47. Spivak J.L. (2002). Polycythemia vera: Myths, mechanisms, and management. Blood 100, 4272-4290.
48. Sterkers Y., Preudhomme C., Lai J.L., Demory J.L., Caulier M.T., Wattel E., Bordessoule D., Bauters F. and Fenaux P. (1998). Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 91, 616-622.
49. Tefferi A. (2000). Myelofibrosis with myeloid metaplasia. N. Engl. J. Med. 342, 1255-1265.
50. Tefferi A. (2001). Recent progress in the pathogenesis and management of essential thrombocythemia. Leuk. Res. 25, 369-377.
51. Thiele J., Laubert A., Vykoupil K.F. and Georgii A. (1985). Autopsy and clinical findings in acute leukemia and chronic myeloproliferative diseases - An evaluation of 104 patients. Pathol. Res. Pract. 179, 328-336.
52. Thiele J., Simon K.G., Fischer R. and Zankovich R. (1988). Follow-up studies with sequential bone marrow biopsies in chronic myeloid leukaemia and so-called primary (idiopathic) osteo-myelofibrosis. Evolution of histopathological lesions and clinical course in 40 patients. Pathol. Res. Pract. 183, 434-445.
53. Thiele J., Zankovich R., Steinberg T., Fischer R. and Diehl V. (1989). Agnogenic myeloid metaplasia (AMM) - Correlation of bone marrow lesions with laboratory data: A longitudinal clinicopathological study on 114 patients. Hematol. Oncol. 7, 327-343.
54. Thiele J., Kvasnicka H.M., Werden C., Zankovich R., Diehl V. and Fischer R. (1996). Idiopathic primary osteo-myelofibrosis: A clinicopathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk. Lymphoma 22, 303-317.
55. Thiele J., Kvasnicka H.M., Boeltken B., Zankovich R., Diehl V. and Fischer R. (1999a). Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - A clinicopathological study. Leukemia 13, 1741-1748.
56. Thiele J., Kvasnicka H.M. and Fischer R. (1999b). Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disoders - Aids to diagnosis and classification. Ann. Hematol. 78, 495-506.
57. Thiele J., Kvasnicka H.M., Schmitt-Graeff A., Bundschuh S., Biermann T., Roessler G., Wasmus M., Diehl V., Zankovich R. and Schaefer H.E. (2000). Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features. Am. J. Clin. Pathol. 114, 57-65.
58. Thiele J., Imbert M., Pierre M., Vardiman J.W., Brunning R.D. and Flandrin G. (2001). Chronic idiopathic myelofibrosis. In: WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Jaffe E.S., Harris N.L., Stein H. and Vardiman J.W. (eds) pp. 35-38. IARC PRess: Lyon.
59. Thiele J., Kvasnicka H.M., Zankovich R. and Diehl V. (2002). Early stage idiopathic (primary) myelofibrosis - Current issues of diagnostic features. Leuk. Lymphoma 43, 1035-1041.
60. Thiele J., Kvascnicka H.M., Schmitt-Gräff A. and Diehl V. (2003). Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: A follow-up study on 309 patients. Leuk. Lymphoma 44, 549-553.
61. van den Berg H., Kluin P.M. and Vossen J.M. (1990). Early reconstitution of haematopoiesis after allogeneic bone marrow transplantation: A prospective histopathological study of bone marrow biopsy specimens. J. Clin. Pathol. 43, 365-369.
62. Weinfeld A., Swolin B. and Westin J. (1994). Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur. J. Haematol. 52, 134-139.
63. Wilkins B.S., Bostanci A.G., Ryan M.F. and Jones D.B. (1993). Haemopoietic regrowth after chemotherapy for acute leukaemia: An immunohistochemical study of bone marrow trephine biopsy specimens. J. Clin. Pathol. 46, 915-921.
64. Wolf B.C. and Neiman R.S. (1985). Myelofibrosis with myeloid metaplasia: Pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 65, 803-809.